Please login to the form below

Not currently logged in
Email:
Password:

Adcetris

This page shows the latest Adcetris news and features for those working in and with pharma, biotech and healthcare.

AZ nabs US approval for new leukaemia drug Lumoxiti

AZ nabs US approval for new leukaemia drug Lumoxiti

Seattle Genetics/Takeda’ s classical Hodgkin lymphoma therapy Adcetris (brentuximab vedotin) and Roche’s Kadcyla (trastuzumab emtansine) for breast cancer.

Latest news

  • Seattle Genetics claims key US approval for Adcetris Seattle Genetics claims key US approval for Adcetris

    did not achieve a complete response, with Adcetris reducing that measure by 23% compared to the control group. ... Crucially, Adcetris avoids the use of the chemotherapy drug bleomycin, which can be associated with severe and unpredictable toxicity.

  • Takeda bags EU approval for Adcetris in lymphoma Takeda bags EU approval for Adcetris in lymphoma

    Takeda bags EU approval for Adcetris in lymphoma. Data shows the drug improves PFS and symptom burden in CTCL patients. ... months on Adcetris, as well as improvements in median progression-free survival (PFS) and overall response rate, and symptom burden

  • Seattle Genetics' Adcetris earns FDA priority review status Seattle Genetics' Adcetris earns FDA priority review status

    Seattle Genetics' Adcetris earns FDA priority review status. The win follows a breakthrough designation from the US regulator last year. ... Seattle Genetics’Adcetris has received a boost after the US Food and Drug Administration’s (FDA) granted the

  • NICE reverses stance on Takeda’s Adcetris NICE reverses stance on Takeda’s Adcetris

    NICE reverses stance on Takeda’ s Adcetris. But firm criticises final draft guidance's new restrictions on the non-Hodgkin’s lymphoma drug. ... Takeda has claimed a partial win for its non-Hodgkin’s lymphoma drug Adcetris (brentuximab vedotin)

  • Keytruda and Opdivo backed for new uses in Europe Keytruda and Opdivo backed for new uses in Europe

    Keytruda is cleared for use in adults who have failed a stem cell transplant and have already tried or are ineligible for Takeda's Adcetris (brentuximab vedotin).

More from news
Approximately 6 fully matching, plus 25 partially matching documents found.

Latest Intelligence

  • Forging a path in specialty care Forging a path in specialty care

    Adcetris (for Hodgkin Lymphoma), Entyvio (for ulcerative colitis and Crohn's Disease) and future compound Ninlaro (an oral protease inhibitor for relapsed/refractory multiple myeloma) which was approved by the FDA

  • Pharma deals during April 2013 Pharma deals during April 2013

    This passion has seemingly been ignited further by the recent FDA approvals of Kadcyla (Genentech/ ImmunoGen) and Adcetris (Seattle Genetics) both following impressive clinic trials in HER2 breast cancer and lymphoma,

  • Interview: Trevor Smith, Takeda Interview: Trevor Smith, Takeda

    Even closer to market is Takeda's monoclonal antibody treatment for Hodgkin's Lymphoma, Adcetris (brentuximab vedotin), which was recommended for European approval in July and which Takeda expects to launch

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics